ReviewJournal of rheumatic diseases2023
Korean treatment recommendations for patients with axial spondyloarthritis.
Review in Journal of rheumatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Korean College of Rheumatology treatment recommendations for patients with axial spondyloarthritis: 2026 update.Journal of rheumatic diseases · 2026Article
- Tumor necrosis factor inhibitor prescribing and persistence by specialty in radiographic axial spondyloarthritis: a Korean claims study.The Korean journal of internal medicine · 2026Article
- Incidence rate and risk factors for interstitial nephritis in patients with ankylosing spondylitis: a nationwide population-based study.Journal of rheumatic diseases · 2026Article
- Defining early axial spondyloarthritis: insights and applications of the Assessment of Spondyloarthritis International Society international consensus.Journal of rheumatic diseases · 2026Review
- Persistence of IL-17 and TNF inhibitors following initial TNF inhibitor use in axial spondyloarthritis: a nationwide retrospective cohort study.Therapeutic advances in musculoskeletal disease · 2026Article
- The impact of nurse-led disease management education on outcomes of patients with ankylosing spondylitis: a randomised controlled trial.Journal of research in nursing : JRN · 2025Article
- Association Between Adalimumab Dosing Interval and Uveitis Recurrence in Patients with Ankylosing Spondylitis.Biomedicines · 2025Article
- Retention rate of TNF inhibitors versus IL-17 inhibitors in ankylosing spondylitis patients with prior biologics experience.Arthritis research & therapy · 2025Article
- Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis.Scientific reports · 2025Article
- Understanding and addressing anti-drug antibody formation in tumor necrosis factor-α inhibitor therapy for ankylosing spondylitis.Journal of rheumatic diseases · 2025Article
- Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea.Rheumatology (Oxford, England) · 2025Article
- Clonorchis sinensis excretory/secretory proteins ameliorate inflammation in rheumatoid arthritis and ankylosing spondylitis.Parasites & vectors · 2025Article
- Biomarkers for successful tapering of a tumor necrosis factor inhibitor in patients with radiographic axial spondyloarthritis: A pilot study.SAGE open medicine · 2025Article
- Association between cumulative TNF inhibitor dose and spinal radiographic progression in radiographic axial spondyloarthritis in patients with modified stoke ankylosing spondylitis spinal score ⩽24.Therapeutic advances in musculoskeletal disease · 2025Article
- Association of the Driving Distance, Driving Time, and Public Transit Time to the Hospital with the Persistence of Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Retrospective Cohort Study.Patient preference and adherence · 2025Article
- Incidence rate of and risk factors for glomerulonephritis in patients with axial spondyloarthritis: a nationwide population-based study.Therapeutic advances in musculoskeletal disease · 2025Article
- Advancements in Imaging Techniques for Early Diagnosis and Management of Axial Spondyloarthritis.Current rheumatology reports · 2024Review
- Social media has become a mainstream source of medical information for patients with rheumatic diseases: a cross-sectional survey of patients.Rheumatology international · 2024Article
- The effectiveness of tumor necrosis factor-α blocker therapy in patients with axial spondyloarthritis who failed conventional treatment: a comparative study focused on improvement in ASAS Health Index.Journal of rheumatic diseases · 2024Article
- Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy.Arthritis research & therapy · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and KMbase. Systematic literature reviews were conducted, quality of evidence was determined, and draft recommendations were formulated according to the Grading of Recommendations Assessment, Development, and Evaluations methodology. Recommendations that reached 80% consensus among a voting panel were finalized. Three principles and 21 recommendations were determined. Recommendations 1 and 2 pertain to treatment strategies, regular disease status assessment, and rheumatologist-steered multidisciplinary management. Recommendations 3 and 4 strongly recommend patient education, exercise, and smoking cessation. Recommendations 5~12 address pharmacological treatment of active disease using nonsteroidal anti-inflammatory drugs, glucocorticoids, sulfasalazine, biologics, and Janus kinase inhibitors. Recommendations 13~16 address treatment in stable disease. We suggest against spa and acupuncture as therapies (Recommendation 17). Recommendations 18 and 19 pertain to total hip arthroplasty and spinal surgery. Monitoring of comorbidities and drug toxicities are recommended (Recommendations 20 and 21). Recommendations for axSpA treatment in a Korean context were developed based on comprehensive clinical questions and evidence. These are intended to guide best practice in the treatment of axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.